• Activating MYD88 as well as nonsense and frameshift WHIM-like CXCR4 somatic mutations are common in WM.
Introduction
Waldenström macroglobulinemia (WM) is an incurable B-cell neoplasm characterized by accumulation of malignant lymphoplasmacytic cells (LPC) in the bone marrow (BM), lymph nodes, and spleen, and excess production of serum immunoglobulin-M (IgM) can produce symptoms related to hyperviscosity, tissue infiltration, and autoimmune-related pathology. 1 The most striking findings from recent whole genome sequencing in WM is the discovery of 2 activating somatic mutations affecting Toll-like receptor and CXCR4 receptor signaling. 2, 3 Approximately 90% to 95% of WM patients carry MYD88 L265P , an activating mutation that triggers interleukin-1 receptor-associated kinase (IRAK) and Bruton's tyrosine kinase (BTK) that in turn activate nuclear factor-kB-p65-dependent nuclear translocation and malignant cell growth. The first reported somatic mutations in CXCR4 in cancer were identified by Hunter et al 3 in 30% of WM patients and involve the carboxyl terminus (C terminus), which contains serine phosphorylation sites that regulate signaling of CXCR4 by its only known ligand SDF-1a (CXCL12). The location of somatic mutations in the C-terminal domain of WM patients are similar to those observed in the germline of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a congenital immunodeficiency disorder characterized by chronic noncyclic neutropenia. 4, 5 Germline mutations in the C terminus of CXCR4 in WHIM patients block receptor internalization after SDF-1a stimulation in myeloid cells that results in persistent CXCR4 activation and BM myeloid cell trafficking. 6 In WM patients, 2 classes of CXCR4 mutations occur in the C terminus. These include nonsense (CXCR4 WHIM/NS ) mutations that truncate the distal 15-to 20-amino acid region and frameshift (CXCR4 WHIM/FS ) mutations that comprise a region of up to 40 amino acids in the C-terminal domain. 3 Nonsense (NS) and frameshift (FS) mutations are almost equally divided among WM patients with CXCR4 somatic mutations. Preclinical studies with the most common CXCR4 WHIM/NS mutation in WM (S338X) have shown enhanced and sustained AKT, extracellular signal-regulated kinase, and BTK signaling following SDF-1a relative to CXCR4
WT as well increased cell migration, adhesion, growth, and survival of WM cells. [7] [8] [9] The clinical implications for MYD88 and CXCR4 somatic mutations in WM remain to be delineated and are the focus of this report.
Patients and methods
BM aspirates and peripheral blood samples were collected after informed written consent from 175 untreated patients with the clinicopathological There is an Inside Blood commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. diagnosis of WM as defined by the Second International Workshop on WM. 10 Consensus criteria were used to delineate patients as having symptomatic vs smoldering disease. 11 The study was approved by the Dana Farber Cancer Institute/Harvard Cancer Center Institutional Review Board. This study was conducted in accordance with the Declaration of Helsinki. MYD88 L265P status was determined using allele-specific polymerase chain reaction, and Sanger sequencing of the C-terminal domain of CXCR4 was performed using sorted (CD19 1 ) lymphoplasmacytic cells (LPC) from BM aspirates as previously reported. 2, 11 The somatic nature of these mutations was confirmed by sequencing CD19-depleted peripheral blood cells.
2,11 SDF-1a tumor sequencing and germline polymorphisms at RS1801157 were available for 54 patients in this study who underwent whole genome sequencing using previously reported methods. 3 
Statistical analysis
Data sets were analyzed by analysis of variance and nonparametric comparisons made by the Fisher's exact probability test. Tukey's honest significant difference test was used for pairwise analysis. Ordinal data were analyzed using pairwise Wilcoxon rank sum test with Holm Bonferroni correction. A P value , .05 was deemed to be significant. A multivariate analysis to estimate risk of death was performed using the Cox proportional hazard regression model. The Fleming-Harrington test was used to assess differences in KaplanMeier survival curves. Calculations were performed with R (R Foundation for Statistical Computing, Vienna, Austria).
Results

MYD88 and CXCR4 status in WM patients
MYD88
L265P was detected in BM LPC from 158/175 (90.3%) patients, and mutations in the C terminus of CXCR4 were present in 51/175 (29.1%) patients. Fifty of 51 patients (98%) who were CXCR4 WHIM -mutated also exhibited the MYD88 L265P mutation ( WHIM/NS demonstrated subclonal populations with other CXCR4 C-terminal mutations. One patient who had a K333X NS mutation had a subclonal population with a 1013C.G (S338X) NS mutation. Another patient with a S338X NS mutation demonstrated a subclonal population with 993_995insA (G332fs) FS mutation. All mutations were confirmed to be somatic in nature by sequencing of corresponding normal paired tissues. 2 The CXCR4 somatic mutations that were identified after Sanger sequencing are annotated for the first time in this report and presented in WT also showed differences in absolute lymphocyte and platelet count vs the 2 other subgroups, but these differences were not clinically meaningful. Of interest, patients with MYD88 L265P CXCR4 WHIM mutations exhibited a lower incidence of adenopathy vs patients with MYD88 L265P CXCR4 WT (P , .01). No differences in gender; absolute neutrophil counts; hemoglobin levels; serum IgA, IgG, and IgM levels; B 2 M levels; presence of splenomegaly; familial history for B-cell malignancies; prior history of monoclonal gammopathy of unknown significance (MGUS); or symptomatic status at diagnosis was observed among these 3 subgroups.
We next examined if differences in clinical presentation existed when NS vs FS CXCR4 WHIM mutation status was delineated ( Table 3) . As shown in Figure 1 WT -mutated (P 5 .04 and .05, respectively). As shown in Table 3, more patients with  MYD88 L265P CXCR4 WHIM/NS also presented with symptomatic disease requiring therapy at diagnosis, which contrasted particularly WHIM/NS were also more likely to present with symptomatic hyperviscosity, reflecting the higher serum IgM levels observed in these patients at diagnosis (Table 3 ). No differences in gender, absolute lymphocyte counts, hemoglobin levels, serum IgA and IgG levels, B 2 M levels, presence of splenomegaly, familial history for B-cell malignancies, or prior history of MGUS were observed among the 4 subgroups. Clinically not meaningful differences in absolute neutrophil and platelet counts were also observed (Table 3) . For 54 patients, both tumor and germline sequencing data for SDF-1a were available. No somatic mutations in SDF-1a were observed in these patients. The distribution for SDF-1a polymorphisms at RS RS1801157, which are associated with increased SDF-1a transcriptional activity, did not vary from those reported in healthy donors, 12, 13 nor did MYD88 (P 5 1.0) or CXCR4 mutations (P 5 .763) show any correlation with RS1801157 SDF-1a polymorphisms in these patients.
MYD88 and CXCR4 mutation status and overall survival in WM
The median follow-up for all patients was 4.84 (range 0.65-23.45) years from time of diagnosis and did not differ among the 4 subgroups (P 5 .51). There were no significant differences in the number of therapies or the percentage of patients who received rituximab, alkylators, proteasome inhibitors, or immunomodulatory agents among the 4 subgroups ( 
CXCR4
WHIM/FS received proteasome inhibitor therapy (P 5 .009).
Fifteen patients died during follow-up, with cause of death attributed to progressive or transformed disease (n 5 11), other cancers (n 5 2), treatment-related myelodysplasia (n 5 1), and amyotrophic lateral sclerosis (n 5 1 
Discussion
This is the first study to address the clinical findings associated with 2 newly discovered somatic mutations (MYD88 L265P and CXCR4) in WM. A paucity of knowledge for these mutations in cancer exists because of the low prevalence of the MYD88 L265P mutation in other B-cell diseases as well as the fact that CXCR4 somatic mutations have not been previously described in any malignant condition despite the often-reported dysregulation of this gene in other cancers. 4 Important strengths of this study are the relatively large genotyped population of WM patients and the long median follow-up (almost 5 years) from diagnosis. The key findings that emerged from this study are that distinct subsets of patients can be identified based on mutational analysis of MYD88 and CXCR4. Patients with MYD88
L265P
CXCR4
WHIM/NS showed higher BM disease burden, higher serum IgM levels, and were more likely to have symptomatic disease requiring therapy at presentation. In contrast, patients with MYD88 WT CXCR4
WT showed the lowest BM disease burden, whereas patients with either MYD88 , regardless of whether they had an NS or FS mutation, were also less likely to have adenopathy. These findings suggest an increased tropism for CXCR4 WHIM -mutated WM cells for the BM stroma, which promotes homing and adhesion of CXCR4 expressing WM cells by elaboration of SDF-1a.
14 Adhesion to the BM stroma promotes malignant cell survival and IgM release, which could account for the more pronounced BM involvement and serum IgM levels that were particularly observed in CXCR4 WHIM/NSmutated patients. WHIM/NS showed more aggressive disease features at presentation, including higher BM disease burden, serum IgM levels (which were nearly double), and symptomatic status including hyperviscosity syndrome requiring therapy vs CXCR4 WHIM/FS -mutated patients. These findings likely contributed to the finding of higher proteasome inhibitor use in CXCR4 WHIM/NS -mutated patients, because bortezomib is recommended by consensus and National Comprehensive Cancer Network guidelines in patients presenting with symptomatic hyperviscosity. 15, 16 The findings also suggest that NS and FS mutations involving the C terminus of CXCR4 behave differently. In WHIM syndrome patients, very few have been identified with FS mutations, and nearly all of these patients have NS mutations (R334X or S338X). 4, 17 As such, little or no preclinical modeling has been done to understand the activating nature of CXCR4 C-terminal domain FS mutations. In the C terminus, at least 6 serines are phosphorylated in response to SDF-1a, beginning with serine 321. 5 Both G proteincoupled receptor kinases (2 and 6) and arrestins (b1 and b2) bind to the C-terminal domain of CXCR4 at different serine residues, resulting in both positive and negative modulations of CXCR4 signaling. Rapid attenuation of CXCR4 signaling follows SDF-1a ligation, which is mediated by recruitment of arrestins, and is dependent on the phosphorylation of the terminal 5 serines that include serines 346/347 that modulate the phosphorylation of more proximal serines. 5, 18 As such, NS mutations such as S338X and R334X that truncate the more distal portions of the C terminus may affect more proximal serine phosphorylation as well as remove a scaffold critical for arrestin binding, thereby promoting prolonged CXCR4 signaling. Preclinical modeling comparing CXCR4 WHIM/NS with CXCR4 WHIM/FS will be required to clarify any signaling differences in response to SDF-1a, which might also be amenable to therapeutic exploitation.
The potential to translate the findings of MYD88 and CXCR4 mutations into therapeutic gains for WM patients is noteworthy.
Both IRAK 1 and 4 as well as BTK signal for MYD88 L265P, whereas BTK is activated by CXCR4. 8, 19 Inhibitors to IRAK are in clinical development, whereas the BTK inhibitor ibrutinib has shown impressive activity in relapsed and refractory WM patients. 18 Major responses to ibrutinib therapy are higher in MYD88 L265P and CXCR4 WT patients, the latter being highly associated with ibrutinib response. 20 In preclinical studies, WM cells engineered to express the S338X CXCR4 NS mutation show resistance to the suppressive effects of ibrutinib on AKT and extracellular signal-regulated kinase 1/2 signaling, which could be restored by use of the CXCR4-specific inhibitor plerixafor. 8 Taken together, these studies highlight the importance of understanding both MYD88 and CXCR4 mutation status in WM and may provide the basis for a more personalized treatment approach, including the use of relevant inhibitors for MYD88-mutated patients and the use of CXCR4 inhibitors in CXCR4-mutated WM patients. In addition to plerixafor, several other antagonists to CXCR4 have been developed and are in clinical trials-including BMS-936564, AMD-070, and TG-0054-and could be investigated for use either alone or in combination treatment strategies for WM patients with CXCR4 mutations.
Despite the aggressive presentation of patients harboring CXCR WHIM/NS mutations, overall survival for these patients was not adversely impacted. A similar number of deaths occurred in both CXCR4 WT (6%) and WHIM-mutated (4%) patients who harbored the MYD88 L265P mutation. Poulain et al 13 reported that a germline polymorphism in SDF-1a (-801GG) at RS1801157 was associated with shorter survival after initiation of therapy in WM patients. We observed no somatic mutations in SDF-1a for 54 patients in this study whose tumor cells were sequenced, nor did MYD88 or CXCR4 mutations correlate with RS1801157 SDF-1a polymorphisms determined by germline sequencing in these patients. Prospective studies incorporating SDF-1a polymorphisms and CXCR4 mutation status in assessing treatment response, progression-free, and overall survival in WM patients could nonetheless be illuminating and help better clarify the predictive and prognostic roles of SDF-1a and CXCR4 variants alone and together. Kaplan-Meier plot for overall survival of 175 WM patients from time of diagnosis stratified by MYD88 and CXCR4 mutation status. Differences in survival curves based on CXCR4 and MYD88 mutation status were significant (P , .0001), as was the analysis based on MYD88 status alone (P , .0001) by Fleming-Harrington log-rank analysis. WT WM disease and the development of targeted and more effective treatments for this patient population.
In summary, we report that MYD88 and CXCR4 mutation status denotes important differences in disease presentation for patients with WM, including BM disease burden, presence of extramedullary disease, serum IgM levels, symptomatic status at diagnosis including presentation with hyperviscosity syndrome, and overall survival. In addition, these studies provide the first reporting of clinical differences in cancer patients associated with CXCR4 somatic mutations, including NS and FS mutation status. These studies also provide a framework for the investigation of MYD88 and CXCR4 mutations as prognostic and predictive markers as well as the development of targeted therapeutics for use in personalized treatment approaches to WM.
